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Reply to: ‘‘Transarterial therapies for hepatocellular carcinoma
(HCC): A long way towards standardization’’
To the Editor:
Chemoembolization is an important treatment for hepatocellular
carcinoma (HCC) and has been shown to improve survival com-
pared with best supportive care in two randomized controlled
trials [1,2]. It is also the current standard of care for intermediate
HCC as deﬁned by the Barcelona Clinic Liver Cancer (BCLC) stag-
ing system [3]. The commonly used method of ‘‘conventional’’
transcatheter arterial chemoembolization involves intra-arterial
infusion of lipiodol mixed with anticancer drugs such as doxoru-
bicin into the feeding artery of the HCC. However, as you are
probably aware, various techniques are used in chemoemboliza-
tion for HCC, but there is a lack of standardization across them
[4]. The method used for chemoembolization is different in East-
ern, including Korea, and Western countries, and the actual
details of the technique vary between interventional radiologists
in the same medical center as well as between medical centers in
the same country. Therefore, a physician may have difﬁculty in
predicting the therapeutic efﬁcacy of chemoembolization and
has a question about that such difference of technical details
could result in different outcomes. Combination of sorafenib with
chemoembolization might complement such pitfalls of
chemoembolization.
In chemoembolization, the gelfoam particles are generally
used as the embolic materials that are injected after sufﬁcient
infusion of lipiodol mixture into the feeding artery. This maxi-
mizes the embolic effect, blocks blood ﬂow into the tumor, and
impedes the washout of lipiodol. However, there is a risk of ische-
mia of the extratumoral liver tissue, resulting in biliary strictures,
bile duct cysts and, as known, VEGF surge. We consider that gel-
foam particle infusion increases the risk of ischemic complica-
tions, and, in our center, we have restricted their use in
chemoembolization to help achieve superselection of the feeding
artery. We use two different methods for chemoembolization in
daily practice. In cases where there are several small nodular type
HCC, we try to select the single feeding artery of each tumor, and
to achieve complete necrosis of the tumor we use aggressive
chemoembolization, referred to as ‘‘angiographic subsegmentec-
tomy’’ [5]. In other cases, we try to minimize normal liver paren-
chymal damage or ischemic complications by using
chemoembolization. The cases in our clinical study [6] included
multiple and/or large tumors, and therefore, the superselection
of multiple feeding arteries for chemoembolization could not be
achieved. If we had used gelfoam particles in these cases, the inci-
dence of ischemic complications might have increased and
administration of sorafenib would be more delayed.
We would not expect all chemoembolization treatments to
have maximal therapeutic effect because of the reasons described
above. Combined treatment with chemoembolization and sorafe-
nib may be an appropriate therapeutic option for these patients.
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Fondaparinux (Arixtra⁄) hepatotoxicity in a 6 year-old child
To the Editor:
Fondaparinux (Arixtra⁄) is a synthetic pentasaccharide, which
selectively binds to antithrombin (AT) and causes a rapid and
selective inhibition of Factor Xa [1]. Fondaparinux is effective
at preventing [1] and treating [2] venous thrombosis and has a
valuable place in the treatment of patients with acute coronary
syndrome [3]. Fondaparinux has been reported to be well toler-
ated and thrombocytopenia has only been reported as isolated
occurrences [4]. It does not undergo hepatic metabolism and
does not interact with liver function [5]. Liver toxicity induced
by fondaparinux has not yet been described. We report a case
of acute hepatitis likely related to fondaparinux administration
in a 5 year-old child who presented with a left-sided axillary
veno-lymphatic malformation diagnosed at 9 days of life.
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Table 1. Timing of drug administration and results of liver function tests.
20/06 21/06 22/06 23/06 24/06 25/06 26/06
1 h
2 h
3 h
4 h Codeine phosphate 8 ml
5 h
6 h
7 h
8 h Fondaparinux sodium 
2 mg
Acetaminophen 200 mg 
+ codeine phosphate 
8 ml + fondaparinux 
sodium 2 mg
Acetaminophen 150 
mg suppo + enoxaparin 
sodium 0.17 ml 
Acetaminophen 200 mg 
+ codeine phophate 8 ml 
Acetaminophen 200 mg 
+ codeine phosphate 
8 ml 
9 h Codeine phosphate 8 ml Enoxaparin sodium 
0.17 ml
Enoxaparin sodium 
0.17 ml
10 h
11 h
12 h
13 h Acetaminophen 200 mg 
14 h
AST 29
ALT 12
GGT 8
Bil 10
ALP 187
AST 374
ALT 433
GGT 157
ALP 27
Nalbuphine 
hydrochloride 2.7 mg
AST 140
ALT 308
GGT 133
ALP 239
AST 48
ALT 194
GGT 113
ALP 214
AST 33
ALT 136
GGT 102
ALP 212
AST 29
ALT 95
GGT 84
ALP 199
15 h
16 h
17 h
18 h
19 h
20 h AST 720 
ALT 509
GGT 161
ALP 278
21 h Acetaminophen 200 mg 
+ codeine phosphate 8 
ml + enoxaparin sodium 
0.17 ml
Acetaminophen 200 mg 
+ codeine phosphate 
8 ml + fondaparinux 
sodium 2 mg 
Acetaminophen 200 mg 
+ codeine phosphate 
8 ml 
Enoxaparin sodium 
0.17 ml
Acetaminophen 200 mg Acetaminophen 200 mg 
+ codeine phosphate 
8 ml
22 h Enoxaparin sodium 
0.17 ml
23 h
24 h Nubain 2.7 mg 
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A 5 year-old child weighing 12 kg was evaluated for persis-
tent pain in the left upper limb probably related to thrombosis
of the previously known vascular malformation. Treatment with
low molecular weight heparin (enoxaparin, 100 IU/kg/d) was
started, which effectively reduced pain. Plasma D-dimer concen-
tration and anti Xa activity were 4000 lg/ml (normal range
<400 lg/ml) and 0.67 IU/ml (normal therapeutic range value:
0.5–1.1 IU/ml), respectively. Five months later, the dose of enox-
aparin had to be increased to 180 IU/kg/d and then to 200 IU/kg/
d nearly one year later because of increase in pain intensity and
enlargement of the malformation. Three days after the last
increase in the dose of enoxaparin, clinical examination dis-
closed a growth of the left axillary tumor and occurrence of a
superﬁcial tuberous angioma. Moreover, the child temperature
rose to 38.6 C. The pain persisted and paracetamol (200 mg/
day orally) and codein (0.6 ml/kg) were introduced. At that time,
the liver function tests were within the reference ranges
(Table 1). Because of the recurrence of pain, enoxaparin was
replaced by fondaparinux (2 mg/day) while paracetamol and
codein were maintained. Thirty hours after the start of fonda-
parinux administration, anti Xa activity was 1.21 lg/ml (normal
therapeutic range value 0.6–1.5 lg/ml) and the child started to
complain of nausea and vomiting. Severe toxic cytolytic hepati-
tis was evidenced with a 15-fold increase in alanine and aspar-
tate aminotransferases (respectively, at ALT 509 and AST 720 IU/
L, normal range: 5–40 IU/L) and a 5-fold increase in glutamyl
transpeptidase (GGT 161 IU/L, normal range: <35 IU/L). Alkaline
phosphatase (ALP 278, normal range: 100–400 IU/L) and biliru-
bin concentrations (Bil 10 lmol/L, normal range: <17 lmol/L)
remained normal (Fig. 1).
Tests for hepatitis A, B, and C serology and viral titration for
herpes, adenovirus, enterovirus, parvovirus B19, HHV6 and
HHV8were all negative. Ultrasound of the liver was normal, with-
out hepatic thrombosis. Fondaparinux was immediately discon-
tinued and enoxaparin was reintroduced (dose: 1700 IU/kg
morning and 1500 IU/kg evening) with no modiﬁcation of the
associated treatment with codeine and paracetamol. Clinical and
laboratory signs of liver injury resolved over the next 5 days with
a return to baseline levels of AST and ALT. Fondaparinux was
considered the probable cause of hepatotoxicity.
This report describes a case of liver toxicity likely due to
fondaparinux administered to a child. The injury was severe
enough to cause both an increase in liver function tests and clin-
ical signs of intolerance. The role of fondaparinux in this case is
highly likely since signs occurred soon after fondaparinux intro-
duction and disappeared rapidly after the drug was stopped.
Other drugs had been used for months without problems and
their use was not modiﬁed soon before the occurrence of liver
toxicity became apparent. There was also no recent change in
the child condition that could be linked to liver injury. We have
not identiﬁed in the literature any previous similar case. The
mechanism of fondaparinux-related hepatotoxicity is still debat-
able. Drug-induced hepatotoxicity is generally idiosyncratic in
nature and diagnosis of drug-induced liver disease can be difﬁcult
to establish since other causes of liver injury cannot be easily
excluded. A transient increase in aminotransferase plasma con-
centrations associated with the use of LMWH has already been
described [5–10].
The heparin-induced effect on liver function appears to be
rather benign [8,10] and the exact pathogenesis is so far
unknown. Various trials in adult human subjects have reported
that fondaparinux is well tolerated. Increase in serum amino-
transferases has been a rare ﬁnding and variations in liver
enzymes were comparable between fondaparinux and placebo
groups or enoxaparin groups. The mechanism of fondaparinux
hepatotoxicity may not be related to the drug metabolites since
in physiological conditions, fondaparinux does not undergo hepa-
tic metabolism, is recovered in the urine as the unchanged com-
pound and does not interact with other drugs administered
concomitantly [4]. One cannot exclude a direct toxicity of the
parent drug in children whose tolerance to fondaparinux has
not yet been evaluated. Moreover, in the present case, inﬂamma-
tory mediators may have contributed to sensitize hepatocytes to
injurious effects of an unknown compound.
Because clinical experience of fondaparinux is limited in chil-
dren, monitoring of liver function tests might be useful especially
in the ﬁrst days after drug introduction.
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Fig. 1. Time proﬁle of liver function tests after introduction and withdrawal
of fondaparinux. AST, aspartate aminotransferase; ALT, alanine aminotrans-
ferase; ALP, alkaline phosphatase; GGT, gamma glutamyltranspeptidase.
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